| Literature DB >> 34483659 |
Jayakumar Perumal1, Hann Qian Lim1, Amalina Binte Ebrahim Attia1, Riazul Raziq1, David Ian Leavesley2, Zee Upton2, U S Dinish1, Malini Olivo1.
Abstract
BACKGROUND: Wound management is stretching the limits of health systems globally, challenging clinicians to evaluate the effectiveness of their treatments and deliver appropriate care to their patients. Visual inspection and manual measurement of wound size are subjective, often inaccurate and inconsistent. Growth factors, such as pro-inflammatory cytokines and proteases, play important roles in cutaneous wound healing. However, little is known about the point-of-care monitoring of the changes in such markers during the healing process. Here, we explore the capability of surface-enhanced Raman spectroscopy (SERS) as a viable point-of-care platform to monitor the changes of these surrogate indicators of healing status in chronic wounds.Entities:
Keywords: SERS; cellulose fibres; flexible biosensor; membrane SERS; paper devices; point-of-care; wound biomarkers
Mesh:
Substances:
Year: 2021 PMID: 34483659 PMCID: PMC8408532 DOI: 10.2147/IJN.S303130
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Schematic illustration showing (A) cellulose fibre SERS substrate fabrication and (B) treatment of cellulose fibre SERS for biomarker proteins sensing.
Figure 2SEM images showing the surface morphology of Ag-coated cellulose fibre substrates at 20 mA with various deposition times: (A) 20 s; (B) 30 s; (C) 40 s; (D) 50 s; (E) 60 s; (F) 80; scale bar (in white) is 200 nm and scale bar (in black) is 100 nm.
Figure 3Evaluation of substrate performance. (A) Plot shows that the maximum SERS signal enhancement was obtained for the cellulose fibre SERS substrate with approximately 60 nm Ag film thickness; (B) Plot shows the uniformity of the substrate signal enhancement across the substrate.
Figure 4Calibration plots of (A) MMP-9 and (B) TNF-α biomarkers, respectively (black circle data points). Red square data points indicate the detection of indicated spiked concentrations of (A) MMP-9 and (B) TNF-α biomarkers from the simulated serum samples using respective calibration plots.
Recovery Studies of MMP-9 and TNF-α in Spiked Samples
| Spiked Analyte | Spiked Concentration (ng/mL) | Recoveries (%) | Relative Standard Deviation (%) |
|---|---|---|---|
| MMP-9 | 25 | 97.1 | 3.1 |
| 125 | 95.3 | 6.2 | |
| 1000 | 90.9 | 2.6 | |
| TNF-α | 5 | 102.6 | 11.9 |
| 25 | 82.8 | 6.7 | |
| 50 | 75.2 | 2.2 |